Vitals Knowledge Vault

Periodontal Pathogens

5 min read

Periodontal Pathogens

TL;DR: P. gingivalis and related periodontal pathogens have detected gingipain antigens in Alzheimer’s disease brains, and observational studies link periodontitis to increased AD risk. However, the COR388 gingipain-inhibitor trial failed its primary endpoints (company went bankrupt 2023), Mendelian randomization shows no causal effect, and P. gingivalis DNA was not significantly elevated in AD brains — only gingipain antigen load. The hypothesis that treating periodontitis prevents or treats AD is not supported by current evidence.

Evidence Grades

ClaimGradeSource
Gingipain antigens detected in AD brains (96% vs 76% controls)BPMID:30746447
Periodontitis → AD risk, pooled OR 1.67–1.78BPMID:35721037, PMID:34247432
Severe periodontitis → AD risk, OR up to 4.89BPMID:34247432
COR388 Phase 2 failed primary cognitive endpointsANCT03823404
Mendelian randomization: no causal effectBPMID:38648391
P. gingivalis DNA not significantly elevated in AD brainsBPMID:30746447 (itself)

Key Facts

  • Organism: Porphyromonas gingivalis — gram-negative anaerobe, keystone pathogen of chronic periodontitis
  • Key virulence factors: Arg-gingipain (RgpA/B), Lys-gingipain (Kgp), PPAD, LPS, OMVs
  • AD brain detection: Gingipain antigens (not DNA) correlate with tau/ubiquitin pathology; detection is not disease-specific
  • COR388 (atuzaginstat): gingipain inhibitor; Phase 2 failed AD primary endpoints → Cortexyme filed Chapter 11 in 2023; acquired by Quince Therapeutics; no active AD development
  • Evidence gap: No large RCT showing periodontal treatment prevents or slows AD

Why It Matters for Vitals

  • Inflammatory biomarker confound: Periodontitis elevates CRP, IL-6, TNF-α — all tracked in Vitals recovery readouts. Oral infection status may explain unexplained inflammatory elevations.
  • Wearable HRV/sleep signal: Poor masticatory performance correlates with sympathetic overactivity (LF/HF ratio); NHANES data link short sleep to severe periodontitis. Direct wearable-measured HRV data in periodontitis patients are lacking (preclinical models only).
  • Recovery interpretation: Active periodontitis may chronically elevate baseline inflammation, distorting CRP/IL-6 trajectories used for training recovery decisions.
  • Oral health as modifiable hygiene factor: Evidence-grade: low-to-moderate. Brushing, flossing, dental cleanings are low-cost, low-risk interventions with general health benefits regardless of AD relevance.

Mechanisms

Gingipain-Mediated Neurotoxicity

Gingipains (RgpA/B, Kgp) are secreted cysteine proteases that directly cleave human proteins including tau, fibrinogen, and hemoglobin. Mass spectrometry identified 44 combined cleavage sites on tau-441 (PMID:30746447). See Gingipain for the dedicated mechanism note.

OMV-Mediated CNS Entry

P. gingivalis outer membrane vesicles (20–250 nm) cross the BBB via transcytosis and deliver gingipains, PPAD, and LPS directly to brain tissue, triggering NLRP3 inflammasome activation and neuroinflammation in mice. See Bacterial OMVs for the cross-cutting mechanism note.

BBB Permeability Increase

Gingipain RgpA activates the Ddx3x/Mfsd2a/Cav-1 axis in brain microvascular endothelial cells, suppressing Mfsd2a and enhancing caveolae-mediated transcytosis (PMID:38414291). This may facilitate both OMVs and whole bacteria in reaching the CNS.

Clinical Evidence

Positive:

  • Dominy et al. 2019 (PMID:30746447): gingipain antigens in 96% AD brains vs 76% controls; gingipain load correlated with tau/ubiquitin pathology (r=0.563–0.786). Industry-funded.
  • Multiple meta-analyses (PMID:35721037, PMID:34247432, PMID:41220116): pooled ORs 1.65–1.78 for AD with periodontitis; severe periodontitis OR up to 4.89.
  • Bidirectional: dementia patients develop periodontitis at higher rates (HR 1.915; PMID:34643147).

Negative / Null:

  • COR388 Phase 2 (NCT03823404, n=643): did not meet co-primary ADAS-Cog 11 or ADCS-ADL endpoints; 40% dropout; 4 deaths in high-dose arm.
  • Mendelian randomization (PMID:38648391): no causal effect of periodontitis on AD.
  • Laugisch et al. 2018 (PMID:30223397): P. gingivalis NOT detected in serum or CSF of AD patients.
  • Ermini et al. 2024 (PMID:38664405): gingipains detected in both PD and neurologically normal control brains — challenges specificity.

Evidence quality flags:

  • Most positive brain-detection studies are industry-funded or authored by Cortexyme-affiliated researchers.
  • Administrative database studies use ICD codes without dental exam confirmation; significant residual confounding.
  • P. gingivalis DNA was 91% in AD brains vs 86% in controls — not statistically significant (PMID:30746447 itself).
  • Reverse causation: AD patients have worse oral hygiene due to cognitive decline.

Biometrics and Wearables

  • HRV: Murine periodontitis models show sympathetic overactivity (elevated LF/APV) but HRV unchanged. Human data limited to poor masticatory performance correlating with higher LF/LF-HF ratio (n=65; PMID:23078535). No direct consumer wearable data.
  • Sleep: NHANES 2013–2014 (n=3,624): sleeping >7 hr associated with 40% lower odds of severe periodontitis; diabetes is strong effect modifier (PMID:31749207). No polysomnography studies.
  • Inflammatory markers: Periodontitis elevates systemic CRP, IL-6, TNF-α — shared pathway with recovery biomarker tracking. P. gingivalis LPS causes neuroinflammation in mice without a large systemic inflammatory signature, suggesting a direct CNS route rather than circulating cytokine elevation.
  • Platelet parameters: PDW and MPV elevated in AD+periodontitis vs AD alone; suggests systemic inflammation as a mediator (PMID:40396318).

Treatment Evidence

Gingipain inhibition:

  • COR388 (atuzaginstat) — failed Phase 2; no ongoing clinical development
  • COR271 (Kgp inhibitor) — reduced brain bacterial load 90% in mice; not advanced to human trials

Antibiotics:

  • Standard antibiotics (moxifloxacin, doxycycline) did not reduce brain bacterial load in mouse models — highlighting why gingipains (not bacterial viability) were the therapeutic target.

Oral hygiene interventions:

  • No adequately powered RCTs testing whether periodontal treatment improves cognitive outcomes in humans.

Limitations of Current Evidence

  1. Causation not established; observational associations with moderate-to-high heterogeneity
  2. Directionality unclear — AD may cause poor oral health rather than the reverse
  3. Independent (non-Cortexyme) replication of brain detection studies is limited
  4. Effect of periodontal treatment on cognitive outcomes — untested in large RCTs
  5. COR388 failure significantly weakens the therapeutic rationale

References

  • PMID:30746447 — Dominy et al. 2019, Sci Adv (P. gingivalis in AD brain)
  • PMID:34247432 — Hu et al. 2021, Psychogeriatrics (meta-analysis periodontitis-AD)
  • PMID:35721037 — Kaliamoorthy et al. 2022, Med Pharm Rep (meta-analysis)
  • PMID:41220116 — Qadir et al. 2025, Clin Exp Dent Res (umbrella review)
  • PMID:38648391 — Mendelian randomization (no causal effect)
  • NCT03823404 — COR388 Phase 2 (GAIN trial)
  • PMID:34643147 — Ma et al. 2022, J Dent Res (bidirectional relationship)
  • PMID:38664405 — Ermini et al. 2024, NPJ Parkinsons Dis (gingipains in normal brains)
  • PMID:38414291 — BBB permeability / gingipain axis
  • PMID:36017373 — OMV neuroinflammation in mice
  • PMID:40396318 — platelet parameters AD+periodontitis
  • PMID:23078535 — masticatory performance HRV
  • PMID:31749207 — NHANES sleep-periodontitis

Graph View

Backlinks